Clinical efficacy of anti‐SARS‐CoV‐2 monoclonal antibodies in preventing hospitalisation and mortality among patients infected with Omicron variants: A systematic …
D Miljanovic, A Cirkovic, I Lazarevic… - Reviews in Medical …, 2023 - Wiley Online Library
Until now, the treatment protocols for COVID‐19 have been revised multiple times. The use
and approval of therapeutic monoclonal antibodies (mAbs) for COVID‐19 treatment …
and approval of therapeutic monoclonal antibodies (mAbs) for COVID‐19 treatment …
Safety and efficacy of combination SARS-CoV-2 neutralizing monoclonal antibodies amubarvimab plus romlusevimab in nonhospitalized patients with COVID-19
TH Evering, KW Chew, MJ Giganti, C Moser… - Annals of internal …, 2023 - acpjournals.org
Background: Development of safe and effective SARS-CoV-2 therapeutics is a high priority.
Amubarvimab and romlusevimab are noncompeting anti–SARS-CoV-2 monoclonal …
Amubarvimab and romlusevimab are noncompeting anti–SARS-CoV-2 monoclonal …
[HTML][HTML] Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Y Yang, F Li, L Du - Journal of Nanobiotechnology, 2024 - Springer
Nanobodies, single-domain antibodies derived from variable domain of camelid or shark
heavy-chain antibodies, have unique properties with small size, strong binding affinity, easy …
heavy-chain antibodies, have unique properties with small size, strong binding affinity, easy …
[HTML][HTML] Evaluation of the neutralizing antibody STE90-C11 against SARS-CoV-2 delta infection and its recognition of other variants of concerns
L Abassi, F Bertoglio, Ž Mačak Šafranko, T Schirrmann… - Viruses, 2023 - mdpi.com
As of now, the COVID-19 pandemic has spread to over 770 million confirmed cases and
caused approximately 7 million deaths. While several vaccines and monoclonal antibodies …
caused approximately 7 million deaths. While several vaccines and monoclonal antibodies …
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
S Iketani, DD Ho - Cell Chemical Biology, 2024 - cell.com
Over four years have passed since the beginning of the COVID-19 pandemic. The scientific
response has been rapid and effective, with many therapeutic monoclonal antibodies and …
response has been rapid and effective, with many therapeutic monoclonal antibodies and …
[HTML][HTML] A tetravalent bispecific antibody outperforms the combination of its parental antibodies and neutralizes diverse SARS-CoV-2 variants
A Chiyyeadu, G Asgedom, M Bruhn, C Rocha… - Clinical …, 2024 - Elsevier
The devastating impact of COVID-19 on global health shows the need to increase our
pandemic preparedness. Recombinant therapeutic antibodies were successfully used to …
pandemic preparedness. Recombinant therapeutic antibodies were successfully used to …
Characterization of treatment resistance and viral kinetics in the setting of single-versus dual-active monoclonal antibodies against SARS-CoV-2
MC Choudhary, R Deo, TH Evering… - The Journal of …, 2024 - academic.oup.com
Background Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether …
[HTML][HTML] Effect of the timing of amubarvimab/romlusevimab (BRII-196/198) administration on progression to severe disease in elderly patients with COVID-19 infection …
Y Xu, Y Liu, R Zheng, S Si, Y Xi, X Deng, G Wang… - Intensive care …, 2023 - Springer
Objective Early intervention with neutralizing antibodies is considered to be effective in
preventing disease progression in patients with mild to moderate COVID-19 infection …
preventing disease progression in patients with mild to moderate COVID-19 infection …
[HTML][HTML] Development of a Single-Chain Fragment Variable that Binds to the SARS-CoV-2 Spike Protein Produced by Genetically Modified Lactic Acid Bacteria
SARS-CoV-2 enters cells via binding of the surface-exposed spike protein RBD to host cell
ACE2 receptors. Therefore, in this study, we designed a scFv (single-chain fragment …
ACE2 receptors. Therefore, in this study, we designed a scFv (single-chain fragment …
[HTML][HTML] Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis
J Zhao, J Zhu, C Huang, X Zhu, Z Zhu, Q Wu… - Frontiers in …, 2022 - frontiersin.org
Background Since the global epidemic of the coronavirus disease 2019 (COVID-19), a large
number of immunological studies related to COVID-19 have been published in various …
number of immunological studies related to COVID-19 have been published in various …